Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Olema Pharmaceuticals, Inc. (Olema Oncology, Nasdaq: OLMA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market, Olema reports key information about its operations, financing activities, and clinical programs through forms such as 8-K, as well as registration statements and prospectus supplements.
Recent Olema 8-K filings include disclosures about an underwritten public offering of common stock conducted under an effective shelf registration statement on Form S-3, the termination of an at-the-market (ATM) prospectus under a sales agreement with TD Securities (USA) LLC, and clinical collaboration agreements with Pfizer to evaluate palazestrant plus atirmociclib in ER+/HER2- metastatic breast cancer. Other 8-Ks furnish press releases reporting quarterly financial results and updated data from Phase 1b/2 studies of palazestrant in combination with ribociclib in advanced or metastatic ER+/HER2- breast cancer.
Through Olema’s SEC filings, investors can review details of its capital-raising transactions, such as the size and terms of public offerings, the use of shelf registration statements on Form S-3, and the structure of underwriting agreements. Filings also identify the company’s registered securities, including its common stock listed under the symbol OLMA on The Nasdaq Global Select Market.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand material events, financial updates, and clinical or collaboration disclosures. Users can monitor new 8-Ks and other SEC reports in real time, track changes related to Olema’s clinical-stage oncology programs, and reference historical filings to follow the evolution of its palazestrant and OP-3136 pipelines and financing history.
Olma Health affiliate transactions: Shane W. Kovacs reported multiple sales of Common stock totaling several tranches in January–February 2026. The filing lists individual sales such as 100,000 shares on 01/15/2026 and smaller tranches on other dates, with cash proceeds shown per trade.
Shawnte M. Mitchell reported insider transactions related to common stock of the issuer. The filing shows a sale of 15,000 common shares on 03/03/2026 for $345,153. It also lists a proposed sale of 25,000 common shares through Fidelity Brokerage Services LLC on 03/04/2026, arising from an option granted on 02/28/2025, to be sold for cash.
Shane W. Kovacs reported proposed sales of Common Stock on Form 144 handled through Fidelity Brokerage Services LLC. The filing lists recent dispositions in the past three months: 01/15/2026 sale of $2,873,214.99 (100,000 shares), 02/23/2026 sale of $723,007.46 (30,000 shares), 02/24/2026 sale of $500,002.00 (20,000 shares), 02/12/2026 sale of $238,498.19 (10,000 shares) and an earlier 01/13/2026 entry of $107,069.20 (3,822 shares). The filing identifies the broker as Fidelity Brokerage Services LLC.
Olami Medical submitted a Form 144 notice reporting a proposed resale of 20,000 common shares on 02/24/2026. The filing lists the securities as restricted stock that vested on 06/15/2020 and shows multiple recent sales by Shane W. Kovacs totaling 143,822 shares across dates in 01/2026 and 02/2026.
OLMA Form 144 filing reports proposed and recent sales of common stock by an insider. The excerpt shows Shane W. Kovacs sold 3,822 shares on 01/13/2026, 100,000 shares on 01/15/2026, and 10,000 shares on 02/12/2026, with dollar amounts listed for each sale. The filing also lists 10,000 shares associated with Fidelity Brokerage Services LLC dated 02/23/2026.
OLMA filer submitted a Form 144 reporting a proposed sale of 20,000 common shares by Fidelity Brokerage Services LLC. The filing also discloses recent reported sales by Shane W. Kovacs, including a sale of 100,000 shares for $2,873,214.99 on 01/15/2026 and 10,000 shares for $238,498.19 on 02/12/2026.
Olema Pharmaceuticals reported that its VP of Finance and Controller, Sasha Lu Austin, acquired equity awards on February 2, 2026. The awards include a stock option for 29,250 shares at an exercise price of $0.00 and a grant of 11,700 shares of common stock, both recorded as awards rather than open-market purchases.
According to the vesting terms, 25% of the option shares vest on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. All holdings are reported as direct ownership.
Olema Pharmaceuticals, Inc. executive Austin Sasha Lu, the VP of Finance and Controller, filed an initial ownership report detailing equity holdings in the company. As of January 30, 2026, Lu directly holds 4,488 shares of common stock and multiple stock option awards. These stock options are structured to vest monthly over multi‑year periods, with several grants featuring 25% vesting on specified initial dates and the remaining 75% vesting in equal monthly installments, all contingent on continued service with Olema.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 6,710,194 shares of Olema Pharmaceuticals, Inc. common stock, representing 8.4% of the class as of 12/31/2025.
The stake is held through various Janus Henderson asset management subsidiaries in discretionary managed portfolios. These asset managers share voting and dispositive power over the shares, while the underlying managed portfolios receive all dividends and sale proceeds. No individual managed portfolio owns more than five percent of Olema’s common stock. Janus Henderson certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Olema.